Article 7: Can PROTACs Truly Become Oral Drugs?
Proteolysis-targeting chimeras (PROTACs) have emerged as a promising therapeutic modality for targeted protein degradation. Rather than inhibiting disease-causing proteins, PROTACs harness the cell's natural protein degradation machinery to selectively eliminate…
Article 6: The 3 Pillars of Bioavailability.
For poorly soluble bRo5 and BCS Class II/IV APls, exposure is driven by the combined effects of solubility, dissolution rate, and permeability-related barriers. Traditional formulation methods, such as ASDs, typically…
Article 5: A Formulation Perspective On Protein Degraders
Abstract Targeted protein degradation has become an important therapeutic approach, with proteolysis targeting chimeras (PROTACs) and molecular glue degraders progressing across multiple drug development programs. By promoting catalytic removal of…
Predicting In Vivo Performance Through In Vitro Partitioning
This case study explores how SeraNovo’s in vitro partitioning assay predicts in vivo exposure for lipid based formulations. Using atazanavir as a representative compound, it highlights how partitioning behaviour, amorphous…
Frequently Asked Questions (FAQ)
Simple answers to the questions we get the most 1. What is NanoGlass™ and how does it work? NanoGlass™ is SeraNovo’s proprietary technology platform that maximizes oral bioavailability by…
